Pfizer

This study tested a new mRNA vaccine to prevent shingles in healthy adults aged 50 to 85. Researchers checked for side effects and how well the vaccine triggered an immune response. The trial was stopped early, so results are limited.

This study aimed to measure how effective the 2024-2025 Pfizer COVID-19 vaccine is at preventing symptomatic infection in real-world settings. Researchers planned to compare vaccinated and unvaccinated people who got tested for COVID-19 at CVS MinuteClinics. The study was termina…

This study tested a new medicine called sisunatovir in infants and children up to 5 years old who had a lung infection caused by RSV. The goal was to check the medicine's safety and how it moves through the body, to help decide the right dose for future studies. The study was sto…

This study tested an oral drug called sisunatovir for adults with RSV who were not in the hospital but had a high risk of getting very sick. Participants took either the drug or a placebo for 5 days. The goal was to see if the drug could prevent hospital stays or death. The study…

This early-phase study tested a new drug (PF-07826390) alone or with another drug (sasanlimab) in 10 people with advanced solid tumors like lung, colon, or kidney cancer. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This study tested an experimental drug called PF-06823859 for adults with lupus that affects the skin. The goal was to see if it could reduce skin symptoms and inflammation. The study was stopped early and only 8 people took part, so results are limited.

This study looked at two different drug combinations for people with advanced melanoma that has a specific BRAF gene change and has gotten worse after prior treatment. One group received a targeted therapy pill (encorafenib and binimetinib) plus an immunotherapy infusion (pembrol…

This study followed 265 people with sickle cell disease who were taking the drug Oxbryta (voxelotor) to see how it worked in everyday life. Researchers measured changes in blood counts, organ function, and complications like pain crises over up to 5 years. The goal was to better …

This study was designed to check the long-term safety of the drug GBT021601 (osivelotor) in people with sickle cell disease who had already taken it in a previous study. It included 47 participants aged 6 months and older. The study was terminated early, so results are limited.

This study aimed to see how well the drug tofacitinib works for people with moderate to severe ulcerative colitis in everyday medical practice in Switzerland. It included 18 adults who were already prescribed the drug. The study was stopped early, but researchers still collected …

This study tested a new drug, elranatamab, combined with other cancer treatments for people with multiple myeloma that had returned or stopped responding to prior therapies. The goal was to find the best dose and see if the combination helped control the disease. The study was te…

This study looked at the long-term safety of the drug voxelotor in 179 people with sickle cell disease who had already taken it in earlier studies. Participants continued taking the drug to monitor side effects and complications. The study was terminated early, but it provided in…

This study tested an experimental oral drug, PF-07054894, in 44 adults with mild to severe ulcerative colitis. The goal was to see if it could safely reduce inflammation and improve symptoms. The trial was terminated early, so results are limited. Participants had active disease …

This study looked at how well the medication abrocitinib works for adults with moderate to severe atopic dermatitis (eczema) in everyday medical practice. About 112 participants in Germany were followed for up to 12 months after starting the drug. The goal was to see how many ach…

This early-phase study tested a new experimental drug, PF-08046032, alone or combined with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the …

This study checks the long-term safety and effects of an experimental gene therapy called fordadistrogene movaparvovec in people with Duchenne muscular dystrophy who received it in a previous Pfizer study. Participants will be followed for up to 10 years with annual visits. The g…

This study tested a drug called voxelotor in children aged 2 to 15 with sickle cell disease who had slightly abnormal blood flow in their brains. The goal was to see if the drug could improve that blood flow and reduce stroke risk. The trial was stopped early, so results are limi…

This early-stage study tested a new drug, PF-07265028, alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, stomach, and head & neck cancers. The goal was to find the safest dose and see if the drugs shrink tumors. The study was terminated early…

This study looked at a combination of three medicines (maplirpacept, tafasitamab, and lenalidomide) for people with diffuse large B-cell lymphoma that had come back or didn't respond to prior treatment. Participants were not able or willing to have a stem cell transplant or CAR-T…

This early-stage study tested a new drug, PF-07820435, alone or with another drug (sasanlimab), in 9 people with advanced solid tumors like lung, skin, and kidney cancers. The main goal was to check safety and find the right dose. The study was stopped early, so results are limit…

This study tested a combination of two experimental drugs (maplirpacept and glofitamab) for people with a type of blood cancer called diffuse large B-cell lymphoma that had come back or not responded to prior treatments. Participants had already tried at least two other treatment…

This early-stage study tested a new drug called PF-08046037, given alone or with another drug (sasanlimab), in people with advanced lung, head and neck, melanoma, or pancreatic cancers. The goal was to check safety and how the body processes the drug. Only 8 people took part befo…

This study tested sasanlimab, an immunotherapy drug, combined with other targeted treatments for people with advanced non-small cell lung cancer (NSCLC). The trial was stopped early, but some participants in one group completed treatment. The goal was to see if the combinations w…

This early-phase study tested a new drug, PF-07284890, alone or with another drug, in people with advanced solid tumors (like melanoma or lung cancer) that have a specific BRAF V600 gene change, including those that spread to the brain. The main goals were to check safety, how th…

This study tested a new drug called PF-08046031 in 11 adults with advanced melanoma or other solid tumors that had spread or had no standard treatment. The goal was to check the drug's safety and side effects. The study was stopped early, so results are limited.

This early-stage study tested an experimental drug (PF-06873600) taken by mouth, alone or with hormone therapy, in people with advanced breast, ovarian, or related cancers. The trial aimed to check safety and how well the drug worked, but it was stopped early. About 155 people we…

This study in Colombia looked at whether a smart injection device (Smartclic) helps people with rheumatoid arthritis stick to their etanercept medication. Researchers reviewed medical records of 60 patients over 40 weeks to track how often they used the device and how their sympt…

This study tested a gene therapy called fordadistrogene movaparvovec in 10 boys with early-stage Duchenne muscular dystrophy. The goal was to see if it was safe and could help their muscles produce a shortened version of the missing protein, dystrophin. The trial was terminated e…

This study looks at the long-term safety of inclacumab in people with sickle cell disease who have already taken the drug in a previous study. It tracks side effects and how often pain crises happen. The goal is to see if the drug remains safe over time.

This study looked at the long-term safety of the drug voxelotor in 162 people with sickle cell disease who had already taken it in earlier studies. The main goal was to track any side effects. The study was stopped early, but the results help doctors understand how safe voxelotor…

This early-phase study tested a new medicine called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, skin, head and neck, or colorectal cancer. The goal was to check safety and how the body handles the dr…

This study looked at whether a full or half dose of the medicine pantoprazole could keep the esophagus healed in children aged 1 to 17 who had healed from a type of severe heartburn called erosive esophagitis. The study planned to follow 43 children for 24 weeks, but it was stopp…

This study tested a single dose of a gene therapy called PF-06939926 in 23 people with Duchenne muscular dystrophy (DMD), both those who could still walk and those who could not. The main goal was to check safety and side effects over one year. The trial was stopped early, but re…

This study tested an experimental drug, PF-07258669, to help older adults (60-90 years) who are at risk of malnutrition or losing weight without trying. The goal was to see if the drug is safe and how it affects the body. The trial was stopped early after enrolling only 7 partici…

This study tested whether a medicine called Ponsegromab could improve symptoms and quality of life in adults with heart failure. Participants received either the drug or a placebo as a shot every four weeks for about 9 months. The trial was stopped early, so results are limited. …

This study aimed to observe how the antibiotic ceftazidime-avibactam is actually used in everyday hospital practice in China. Researchers planned to follow about 450 adult patients with serious infections like pneumonia or abdominal infections. The study was terminated early, so …

This early-stage study tested an experimental drug (PF-07899895) in 37 healthy adults to see if it was safe and how the body processes it. Participants received either the drug or a placebo in different dosing schedules. The study was terminated early, so results are limited.

This early-stage study tested whether the experimental drug PF-07314470 is safe in healthy adults and how the body absorbs and removes it. The trial was stopped early by the sponsor. It involved 23 healthy volunteers aged 18 to 55 who received either the drug or a placebo by inje…